Intravenous apomorphine therapy in Parkinson's disease: clinical and pharmacokinetic observations.
about
Novel pharmacological strategies for motor complications in Parkinson's disease.Advances in the delivery of treatments for Parkinson's disease.Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label resultsTreatment of Parkinson's disease in the advanced stage.Apomorphine therapy in Parkinson's disease: a review.Motor and nonmotor complications in Parkinson's disease: an argument for continuous drug delivery?Apomorphine nodules in Parkinson's disease: best practice considerations.Apomorphine and levodopa infusion therapies for advanced Parkinson's disease: selection criteria and patient management.New non-oral drug delivery systems for Parkinson's disease treatment.Continuous drug delivery in early- and late-stage Parkinson's disease as a strategy for avoiding dyskinesia induction and expression.Subcutaneous infusions of apomorphine: a reappraisal of its therapeutic efficacy in advanced Parkinson's disease.Novel levodopa formulations in the treatment of Parkinson's disease.Apomorphine and levodopa infusion therapies for advanced Parkinson's disease.The role of subcutaneous infusion of apomorphine in Parkinson's disease.Role of apomorphine in the treatment of Parkinson's disease.Apomorphine induces trophic factors that support fetal rat mesencephalic dopaminergic neurons in cultures.Response to levodopa in parkinsonian patients with bilateral subthalamic nucleus stimulation.
P2860
Q36120761-905955D4-E7B6-435E-8986-334703AE36ACQ36316936-8634405F-D5A3-4198-9C85-4F861AB07822Q36361513-9A1185C3-6E26-4406-B9DA-F7C50E53840FQ36725292-EB35B491-2689-4BC4-8264-16454CF054F7Q36979329-4AEDAF11-7997-438E-95B1-082D8524C799Q37115650-5684E3C3-873B-439D-9C83-D800E95F416AQ37341588-39A2316C-96A0-48EE-93FD-A37A6EF7F68CQ37507973-C931E99D-B4C5-40EC-A7AE-654EDF967466Q37840165-64E49553-C6F4-4352-B95F-278B37D900FFQ37924626-03691EFA-5A67-4842-BFD4-1E35CD9E256EQ38155589-480AA8DF-7187-4F11-B897-B1A434F2F71DQ38178754-27C9FE79-8145-4A2C-AEB2-70404F931B06Q38215506-42A3282E-AFF7-46AA-9B3B-3EB03C78D2BAQ38219351-6101BA08-BFEB-461C-9509-1054B1EBBC5EQ38353520-7C14CA73-83BD-4E9B-94B3-25A50955A9E2Q40687525-FDD6DC8C-D550-4456-955E-DEE23B4C49AFQ44187507-1CF0F3D8-6580-4F45-8E4C-B22D8C84165D
P2860
Intravenous apomorphine therapy in Parkinson's disease: clinical and pharmacokinetic observations.
description
2001 nî lūn-bûn
@nan
2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Intravenous apomorphine therap ...... pharmacokinetic observations.
@ast
Intravenous apomorphine therap ...... pharmacokinetic observations.
@en
type
label
Intravenous apomorphine therap ...... pharmacokinetic observations.
@ast
Intravenous apomorphine therap ...... pharmacokinetic observations.
@en
prefLabel
Intravenous apomorphine therap ...... pharmacokinetic observations.
@ast
Intravenous apomorphine therap ...... pharmacokinetic observations.
@en
P2093
P356
P1433
P1476
Intravenous apomorphine therap ...... pharmacokinetic observations.
@en
P2093
P304
P356
10.1093/BRAIN/124.2.331
P407
P577
2001-02-01T00:00:00Z